feature photo

News

Press Releases and Other Research News


IMPAACT P1093 Informs Committee for Medicinal Products for Human Use (CHMP) positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe.

December 21, 2016

This CHMP positive opinion follows the U.S. Food and Drug Administration’s (FDA) paediatric approval in June 2016 of dolutegravir for a reduced age and weight limit. Read More

Sixteen IMPAACT Abstracts Accepted for CROI 2017

December 1, 2016

The IMPAACT Network is pleased to announce that 16 abstracts have been accepted at the 24th Annual Conference on Retroviruses and Opportunistic Infections (CROI) as posters. To view the full listing, click here.


RSV studies achieve robust enrollment

November 7, 2016

IMPAACT is pleased to report that IMPAACT 2011 successfully closed to accrual, and IMPAACT 2012 enrolled 51% of the target accrual before the start of the fall 2016 respiratory syncytial virus (RSV) season. IMPAACT 2011 and 2012 are the first two in a series of three new Phase I studies of the infectivity, safety, and immunogenicity of similar RSV vaccines. In spring 2017, IMPAACT 2012 is expected to complete enrollment, and the third study, IMPAACT 2013, is expected to open to accrual. These studies represent a continued collaborative effort of the IMPAACT network, the National Institutes of Health Laboratory of Infectious Diseases (NIH LID), and the Johns Hopkins University Center for Immunization Research (JHU CIR), and they follow prior collaborative protocols P1096, P1114, and IMPAACT 2000.


Publication of PROMISE Breastfeeding and Formula Feeding Versions Antepartum Results

November 7, 2016

The IMPAACT Network is pleased to announce the antepartum results from the PROMISE Breastfeeding and Formula Feeding Versions (1077BF and 1077FF) were published in the New England Journal of Medicine (NEJM). This part of the PROMISE study demonstrated that triple antiretroviral (ARV) regimens evaluated in the study were superior to the single ARV based regimen for prevention of perinatal transmission during pregnancy and immediately postpartum. Read More


PROMISE studies successfully closed to follow up

October 5, 2016

IMPAACT is pleased to announce that the Promoting Maternal and Infant Survival Everywhere (PROMISE) studies have successfully closed to follow-up. The PROMISE studies are a group of three multi-faceted trials and one sub-study designed to address - in an integrated and comprehensive fashion - critical questions facing HIV-infected pregnant and postpartum women and their infants, including evaluation of the optimal ARV strategies for prevention of antepartum, intrapartum, and postpartum perinatal transmission of HIV and the optimal strategy to preserve maternal health. The studies began in 2010 and included over 9000 mothers and infants across 65 clinical research sites in Africa, Asia, and the Americas. Results from portions of the studies were recently presented at AIDS 2016 and will soon be published in the New England Journal of Medicine.


Request for Applications (RFA)

August 12, 2016

The US National Institutes of Health (NIH)-sponsored International Maternal Pediatric Adolescent Clinical Trials (IMPAACT) Network aims to increase investigator access to and use of stored biological specimens available at both the National Institute of Allergy and Infectious Diseases (NIAID) Biomedical Research Institute (BRI) repository and the Fisher Scientific repository, both in Rockville, Maryland, for new laboratory-based scientific investigations. Read More


>> Read more from 2016 in our News Archive

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.